Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2014
At a glance
- Drugs LY 3108743 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 14 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Mar 2014 Planned End Date changed from 1 Mar 2014 to 1 May 2014, as per ClinicalTrials.gov record.
- 08 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.